Genetics of Symptomatology and Treatment Response in Psychotic Major Depression - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

June 3, 2008

Last Updated Date

June 4, 2008

Start Date ^†

October 2003

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00691535 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Genetics of Symptomatology and Treatment Response in Psychotic Major Depression

Official Title ^†

Association of BDNF, COMT, MDRI, CRH, CRF, and GC Receptor Genetic Polymorphisms With Symptomatology and Treatment Response in Psychotic Major Depression

Brief Summary

We hope to learn more about the biology of psychiatric illness with the hope of improving the diagnosis and treatment of such psychiatric conditions as major depression.

Detailed Description

From the blood sample you donate, the researchers will obtain DNA. This DNA will be used to search for DNA markers related to the underlying biology of psychiatric illness and how this might explain the symptoms of these disorders. Research using DNA is an important way to try to understand human disease and/or the role genes play in disease. In effect, part of your blood sample will be used to attempt to understand how genetic factors contribute to the symptoms of such psychiatric conditions as major depression.

Study Phase

Study Type ^†

Observational

Study Design ^†

Other

Condition ^†

Psychotic Disorders
Depressive Disorder
Depressive Disorder, Major

Intervention ^†

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Recruiting

Enrollment ^†

500

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

You are currently experiencing symptoms that are consistent with an episode of major depression without symptoms of psychosis (such as hallucinations, delusions or disorder of thought process), or
You are currently experiencing symptoms that are consistent with an episode of major depression with symptoms of psychosis (such as hallucinations, delusions or disorder of thought process), or
You have been diagnosed with either schizophrenia or schizoaffective disorder, or
You are a volunteer without a history of psychiatric illness (a healthy control subject).

Gender

Both

Ages

Accepts Healthy Volunteers

Yes

Contacts ^††

Contact: Gregory H Cohen, MSW

(650) 723-3305

ghcohen@stanford.edu

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00691535

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Stanford University

Collaborators ^††

Investigators ^†

Sub-Investigator:

Alan Schatzberg

Stanford University

Information Provided By

Stanford University

Verification Date

June 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.